How to calculate the treatment effect of chronic myeloid leukemia? Under what circumstances can the drug be discontinued?

Click the blue text above to follow us

With the continuous development and progress of medicine, chronic myeloid leukemia is no longer a “terminal disease” strong>, but a condition that can survive for a long time like a “chronic disease”. Most CML patients can achieve long-term stability through timely and effective treatment, and some patients can return to normal life and work.

How to calculate the treatment effect of chronic myeloid leukemia? Under what circumstances can the drug be discontinued?

Hematologists say : The ultimate treatment goal of chronic myeloid leukemia is to reduce the level of BCR-ABL cancer gene in patients to a safe range, or even to completely eliminate it, so as to achieve sustained remission without treatment, that is, “cured” chronic myeloid leukemia.

Achieving this goal requires a complete hematological, cytogenetic and molecular To drug treatment, as far as possible to obtain a deeper molecular response to achieve the standard of drug withdrawal.

The guidelines for the diagnosis and treatment of chronic leukemia suggest that patients should undergo a standardized quantitative PCR (polymerase chain reaction) test every 3 months to observe the level and rate of decline of the BCR-ABL fusion gene in the blood.

BCR-ABL should drop below 10% at 3 months;

6 months to less than 1%;< /p>

12 months should be reduced to 0.1%, ie major molecular remission (MMR) must be achieved.

Achieving the above goals means that the patient’s treatment effect is better. If these goals are not achieved, then, The treatment plan needs to be adjusted according to the specific indicators of the patient. If the treatment effect is not obvious, the treatment plan needs to be changed to avoid further development of the disease.

< > Under what circumstances can patients with chronic myelopathy be discontinued?

Prerequisites for drug discontinuation in patients with chronic granulocytosis: a very good effect after taking TKI drugs (ie Deep remission, at least MR4.5), it should be noted that about half of the patients with very good curative effect can achieve drug withdrawal, and the other half will still relapse and cannot be stopped.

So not all All patients with chronic granulocytosis can meet the standard of drug withdrawal, and patients after drug withdrawal also need toTo monitor the efficacy, if the disease recurs, it is necessary to continue taking the medicine. In addition, patients who have achieved remission cannot stop the drug by themselves, and must gradually reduce and stop the drug after the diagnosis of a professional doctor.

No.15-No.20 Joint Clinic of Experts

width

Appointment entrance is open…

Due to consultation Space is limited and by appointment only. If the patient is currently troubled by blood diseases and cannot find an effective treatment method, it is recommended to make an appointment for this joint consultation with experts in time.

Entry by appointment

↓↓↓